Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

NCT03662035 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Advanced Pancreatic Cancer

Interventions

DRUG: Apatinib
DRUG: S-1

Sponsor

Changzhou No.2 People's Hospital